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Interleukin 6 (IL-6) is known as a multifunctional cytokine which plays a central role in the host defence mechanism by regulating immune responses, haematopoiesis and acutephase reactions (Kishimoto, 1989) . Recently, much attention has been focused on its role in the pathogenesis and progression of various malignancies. It has been reported that IL-6 is an autocrine growth factor for renal cell carcinoma cells (Miki et al., 1989; Koo et al., 1992) and that IL-6 is produced by other non-haematopoietic tumour cells, including bladder carcinoma (Rawle et al., 1989) , ovarian carcinoma (Watson et al., 1990) and glioblastoma (Meir et al., 1990) . In animal systems, IL-6 appears to have an important role in mediating cancer cachexia (Strassmann et al., 1992) . More- over, elevation of the serum IL-6 level is an adverse prognositic factor in patients with metastatic renal cell carcinoma (Blay et al., 1992) . However, there is still little information about the role of IL-6 in vivo in patients with various malignancies.
In patients with lung cancer, we have already reported that malignant pleural effusions contain IL-6 (Yanagawa et al., 1992) , and we (Mizuno et al., 1994) and others (Matsuguchi et al., 1991) have reported that several lung cancer cell lines constitutively produce IL-6 in vitro. To clarify further the role of IL-6, we examined serum levels of IL-6 in patients with lung cancer. The relationship between serum IL-6 levels and the characteristics of the patients was also analysed.
Materials and methods

Patients
Seventy-five patients with lung cancer were examined before receiving anti-cancer therapy in Tokushima University Hospital. Lung cancer was diagnosed by either histological or cytological examination of sputum or specimens obtained by bronchofibrescopy, percutaneous needle biopsy or thoracotomy. Lung cancer was staged according to the tumournode-metastasis classification system (Union Internationale Contre le Cancer, 1987 Enzyme immunoassay of IL-6 Serum levels of IL-6 were assayed essentially as described previously (Yanagawa et al., 1992) . In brief, microtitre plates (Nunc, Naperville, IL, USA) were coated with anti-IL-6 monoclonal antibody in 100 per well phosphate-buffered saline (PBS). After overnight incubation at 4°C, the wells were blocked with 0.1% bovine serum albumin (BSA) in PBS and washed three times. Volumes of 200 MI of test samples were added to the duplicate wells. The plates were incubated at 37C for 24 h. After washing, 100 fl of mouse anti-IL-6 antibody was added to each well. The plates were then incubated for 2 h at 37C, washed three times, supplemented with 100 il of peroxidase-labelled rabbit anti-mouse IgG + IgA + IgM (H + L) (Zymed Laboratories, San Francisco, CA, USA) and incubated at room temperature for 2 h.
Finally the plates were washed five times, 1001 of enzyme substrate (1 mg ml-' O-phenylenediamine (OPD) in 0.1 M sodium citrate buffer, pH 5.0) was added to each well and the plates were incubated at room temperature for 5 min. The reaction was stopped by adding 100I l of sulphuric acid to each well, and the absorbance of 492 nm was determined using a Titertek Multiscan. The sensitivity limit is 20 pg ml-' and lower levels were considered undetectable.
Measurement of blood platelet counts and levels of C-reactive protein, albwnin andfibrinogen Blood platelet counts, plasma fibrinogen levels and serum levels of C-reactive protein (CRP) and albumin were measured as a routine examination in our hospital.
Statistical anatysis
Results are expressed as means ± standard error of the mean. The statistical significance of differences between groups was analysed by Student's t-test. Data were considered statistically significant if P-values were <0.05.
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Results Serum IL-6 levels in patients with lung cancer Of 75 patients with lung cancer, 29 (39%) had detectable serum IL-6 levels. The individual data for cancer histological types are shown in Figure 1 . IL-6 was detected in 12 of 24 patients (50%) with squamous cell carcinoma, in 10 of 27 patients (37%) with adenocarcinoma, in 6 of 20 patients (30%) with small-cell carcinoma and one of four patients (25%) with large-cell carcinoma. In contrast, no patient with benign lung diseases had detectable serum IL-6 levels. Although Ershler et al. (1993) reported that the plasma levels of IL-6 rise with advancing age, there was no significant difference in age between any of the groups in the present study, as shown in Table I .
Levels of CRP andfibrinogen in lung cancer patients with or without detectable serum IL-6 levels Since IL-6 is reported to stimulate hepatic protein synthesis in vitro (Ramadori et al., 1988; Castell et al., 1989) , we examined hepatic protein levels in lung cancer patients and patients with benign lung diseases. Serum CRP and plasma fibrinogen were examined as hepatic proteins. As shown in Figure 2 , patients with detectable serum IL-6 levels had significantly higher serum CRP levels (65.9 ± 2.9 mg 1') than patients without detectable serum IL-6 levels (18.2 ± 0.9 mg l'; P <0.05) and patients with benign lung diseases (8.1 ± 0.7 mg dl-1; P<0.01). Moreover, as shown in Figure  3 , patients with detectable serum IL-6 levels had significantly higher plasma fibrinogen levels (4.67 ± 0.65 g 1') than patients without detectable serum IL-6 levels (3.80 ± 0.38 g I-'; P <0.05) and patients with benign lung diseases (3.21 ± 0.70 g -l1; P<0.05). (Ikebuchi et al., 1987; Ishibashi et al., 1989) , we studied the possible correlation between serum IL-6 concentrations and blood platelet counts. As shown in Figure 4 , there was no significant difference in blood platelet counts between lung cancer patients with detectable (26.5 ± 0.51 x 104 il-1) or undetectable (26.1 ± 0.20 x 104ylh 1) serum IL-6 levels or patients with benign lung diseases (30.1 ± 0.33 x 104 ll-1). In the present study. we demonstrate that patients with lung cancer have elevated levels of IL-6, and that lung cancer patients with detectable serum IL-6 levels have significantly higher CRP and fibnrnogen levels and lower albumin concentration than those without serum IL-6 levels and patients with benign lung diseases.
Elevated serum IL-6 levels have already been reported in elderly subjects (Ershler et al., 1993) al., 1988) and systemic lupus erythematosus (Spronk et al., 1992) . In the present study, there was no significant difference in age between patients with benign lung diseases and patients with lung cancer of various histological types, and patients with possible complications of benign diseases in which elevated serum IL-6 levels have been reported were strictly excluded. The mechanism responsible for the elevated levels of serum IL-6 in lung cancer patients remains unclear. It could be the result of abnormal production by tumour cells or a response of the immune system im the tumour-bearing state.
IL-6 is known to induce production of acute-phase proteins by hepatocytes (Ramadori et al., 1988; Castell et al.. 1989) . In our study, as observed previously by others in patients with renal cell carcinoma (Blay et al., 1992) , serum CRP levels in patients with detectable serum IL-6 levels were significantly higher than in those with undetectable levels.
Moreover, as shown in Figure 3 , plasma fibrinogen levels had the same correlation as CRP with serum IL-6 levels.
We have found that lung cancer patients with detectable serum IL-6 levels have lower serum albumin concentrations than those without detectable serum IL-6 levels. Dosquet et al. (1994) have already reported that renal cell carcinoma patients who experience weight loss have higher blood IL-6 levels than those without weight loss. As reported in animal models (Strassmann et al., 1992) , systemic IL-6 can be considered a mediator of malnutrition in lung cancer patients.
Megakaryocytopoiesis, resulting in the production and release of platelets, is regulated by various cytokines, including IL-1, IL-2, IL-3, IL-6, IL-7, IL-l1, granulocyte colonystimulating factor (CSF), macrophage CSF and granulocyte-macrophage CSF (Ogawa, 1993) . Among these, IL-6 is reported to stimulate platelet production in animal models (Asano et al., 1990; Hill et al., 1990) . Moreover, increased blood platelet counts were observed in a phase I study of subcutaneous administration of IL-6 (Wever et al., 1993) . Nevertheless, no significant thrombocytosis was observed in patients with detectable serum IL-6 levels in the present study. The reason for this discrepancy is unclear, but it is possible that the elevated IL-6 levels observed in patients with lung cancer are lower than required for stimulation of thrombopoiesis or that other additional cytokines necessary for thrombopoiesis were lacking in these patients.
There are several reports suggesting that IL-6 contributes to tumour progression directly and indirectly through inhibition of the anti-tumour response by host cells. In a murine model, IL-6 has been shown to enhance tumour progression, and local inhibition by IL-6 of the anti-tumour response by tumour-infiltrating lymphocytes has been suggested (Tanner and Tosato, 1991). Moreover, Dosquet et al. (1994) have reported that renal cell cancer patients with disseminated disease have higher blood IL-6 levels than those with undisseminated disease. On the other hand, detectable serum levels of IL-6 are less and less frequent with progression of IB-cll chronic lymphocyic leukemia (Aderka et at., 1993 carcinoma (Miki et al., 1989; Koo et al., 1992) as well as multiple myeloma (Kawano et al., 1988) 
